EPAS1 and hepatocellular carcinoma: The addition of metformin to sorafenib treatment inhibits HIF-2α protein expression in vitro and in an orthotopic xenograft mouse model, which allows recovery of HCC cells sensitivity to sorafenib-induced apoptosis [54].